



BRINGING SCIENCE TO LIFE

PRESS RELEASE

Avesthagen Limited Forms JV in Its Subsidiary Dhanvantari Botanicals for Wellness

Bangalore, October 30, 2011: Avesthagen Limited (Bangalore), a fully integrated life sciences genomic healthcare company with a predictive, preventive, personalized approach to healthcare, and SAVA Medica Limited (Pune), an emerging fast growing global pharmaceutical company with business verticals across the pharma value chain have formed a 50:50 joint venture in Avesthagen Limited's Dhanvantari Botanicals subsidiary to market and sell a line of Avesthagen Limited bioactive products in the U.S. and BRIS (Brazil, Russia, India, and South Africa). Dhanvantari Botanical's products include 11 OTC brands (AmlaPure™, Ashwagandha™, BosWell™, Gymnema™, ThinkWell™, Tribulus™, Triphala™, TriplaLax™, WinterWell™, XanoMax™, and GojiMax™) and highly qualified bulk ingredients for the wellness and nutraceutical markets.

With this joint venture agreement, Avesthagen grants and SAVA Medica Limited earns exclusive marketing rights for Avesthagen's 7 lead first generation scientifically validated and clinically active research products (AvestaDHA™, Smartchol™, Prova™, Teestar™, Cincata™, Bonaphyte™, and Phytossea™) from Avesthagen Limited's portfolio for OTC-formulated tablet (including child-convenient dose such as fast-dissolving tablet), capsule and liquid forms for medical use in BRIS countries.

Dr. Viloo Morawala-Patell, Founder and CMD of Avesthagen Limited, said: "This transaction mirrors the clear segregation of the nutrition industry into general wellness, preventive nutraceuticals, and medical nutrition. This deal falls under general wellness for the 11 OTC products (AmlaPure™, Ashwagandha™, BosWell™, Gymnema™, ThinkWell™, Tribulus™, Triphala™, TriplaLax™, WinterWell™, XanoMax™, and GojiMax™) and under preventive nutraceuticals for the 7 bioactive products (AvestaDHA™, Smartchol™, Prova™, Teestar™, Cincata™, Bonaphyte™, and Phytossea™). Avesthagen Limited will continue on the path to bringing more products available to consumers in its move towards medical nutrition. This partnership provides a great opportunity for entry into the emerging markets strong revenue stream for Avesthagen Limited." Under the terms of the deal, Avesthagen Limited will receive upfront payments and a 15% royalty on product net sales in the stated territories.

Avesthagen Limited is the first genomics healthcare company to promote the Predictive Preventive Personalized Healthcare™ model worldwide which is based on achieving convergence between food, pharma and population genetics. This transaction is part of Avesthagen Limited's business strategy to bring proprietary technologies and products, diagnostics, functional foods, and biological therapeutics focusing on metabolic disorders, cancer and neurodegenerative disorders to consumers through partnerships.

Avesthagen Limited is poised to capture a large part of the healthcare (diagnostic, wellness, and therapeutic) market worldwide which is growing by 20% to 30% per year in spite of the global recession through a series of strategic business deals.

Mr. Vinod Jadhav, Founder and Managing Director of SAVA Medica Limited, said: "We at SAVA Medica Limited look forward with great optimism to this strategic business partnership with Avesthagen Limited and to promoting this line of wellness and nutrition products in BRIS and the U.S. Our collective commitment to human healthcare is reflected in this joint venture that will benefit large populations in the emerging markets by providing access to these excellent preventive healthcare and general wellness products. With our strong sales and marketing force and vital manufacturing and research capabilities in-built in our geosystem, we are now well-positioned to capture a significant share of the global consumer healthcare market with such definitive value-added products."

SAVA Medica Limited (Pune), is an integrated research based innovative healthcare company with a strong global distribution, sales and marketing network. Sava Medica Limited has an approximately 150-person sales force to market products in India and a significant ground presence in the other BRIS countries. Sava Medica

Limited develops and distributes a wide range of healthcare products for various human health ailments including respiratory, cardiovascular, antineoplastics, and anti-infectives.

This joint venture sets the footprint of SAVA Medica Limited in the US\$102B global nutraceuticals market.

About Avesthagen Limited:

Avesthagen is India's leading integrated systems biology platform company that focuses on achieving convergence of food, pharma and population genetics leading to predictive preventive and personalized healthcare. Avesthagen partners include multiple top 10 global companies in each of its fields of research. Since its inception Avesthagen has grown into one of India's leading healthcare biotech companies. In addition to its agri-biotechnologies product pipeline, it has developed clinically validated botanical bioactives and a strong pipeline of bio-similars.

ww.avesthagen.com

Contact anilram@avesthagen.com